BioLineRx Ltd. (TLV:BLRX)
1.500
0.00 (0.00%)
May 15, 2026, 11:35 AM IDT
BioLineRx Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 3.25 | 10.44 | 4.26 | 10.59 | 12.99 |
Short-Term Investments | 17.63 | 9.13 | 38.74 | 40.5 | 44.15 |
Cash & Short-Term Investments | 20.88 | 19.56 | 42.99 | 51.08 | 57.14 |
Cash Growth | 6.72% | -54.50% | -15.83% | -10.59% | 152.95% |
Accounts Receivable | 0.05 | 2.48 | 0.36 | - | - |
Other Receivables | 0.41 | 1.39 | 0.35 | 0.72 | 0.14 |
Receivables | 0.46 | 3.86 | 0.71 | 0.72 | 0.14 |
Inventory | 2.15 | 3.15 | 1.95 | - | - |
Prepaid Expenses | 0.2 | 0.44 | 1.05 | 0.2 | 0.13 |
Other Current Assets | - | 0.09 | 0.48 | - | - |
Total Current Assets | 23.68 | 27.1 | 47.18 | 52 | 57.4 |
Property, Plant & Equipment | 0.86 | 1.35 | 1.89 | 2.5 | 2.28 |
Other Intangible Assets | 16.37 | 10.45 | 14.85 | 21.89 | 21.7 |
Total Assets | 40.91 | 38.91 | 63.93 | 76.38 | 81.39 |
Accounts Payable | 3.49 | 5.58 | 10.87 | 6.97 | 5.57 |
Accrued Expenses | 1.21 | 3.13 | 3.27 | 1.66 | 1.23 |
Current Portion of Long-Term Debt | 4.48 | 4.48 | 3.15 | 1.54 | 2.76 |
Current Portion of Leases | 0.23 | 0.52 | 0.53 | 0.43 | 0.17 |
Current Unearned Revenue | - | - | 12.96 | - | - |
Other Current Liabilities | 2.71 | 1.69 | 12.02 | 0.08 | 0 |
Total Current Liabilities | 12.12 | 15.41 | 42.78 | 10.68 | 9.72 |
Long-Term Debt | 4.46 | 8.96 | 6.63 | 8.63 | - |
Long-Term Leases | 0.98 | 1.08 | 1.29 | 1.73 | 1.73 |
Other Long-Term Liabilities | - | - | - | 4.51 | 1.86 |
Total Liabilities | 17.56 | 25.45 | 50.7 | 25.54 | 13.3 |
Common Stock | 73.43 | 38.1 | 31.36 | 27.1 | 21.07 |
Additional Paid-In Capital | 327.58 | 353.69 | 355.48 | 338.98 | 339.35 |
Retained Earnings | -401 | -399.83 | -390.61 | -329.99 | -305.04 |
Comprehensive Income & Other | 18.19 | 21.5 | 16.99 | 14.76 | 12.72 |
Total Common Equity | 18.2 | 13.46 | 13.22 | 50.84 | 68.09 |
Minority Interest | 5.15 | - | - | - | - |
Shareholders' Equity | 23.35 | 13.46 | 13.22 | 50.84 | 68.09 |
Total Liabilities & Equity | 40.91 | 38.91 | 63.93 | 76.38 | 81.39 |
Total Debt | 10.15 | 15.04 | 11.59 | 12.32 | 4.65 |
Net Cash (Debt) | 10.73 | 4.52 | 31.4 | 38.76 | 52.48 |
Net Cash Growth | 137.20% | -85.60% | -18.98% | -26.15% | 252.17% |
Net Cash Per Share | 0.00 | 0.00 | 0.03 | 0.05 | 0.08 |
Filing Date Shares Outstanding | 2,611 | 2,233 | 1,087 | 922.96 | 715.16 |
Total Common Shares Outstanding | 2,611 | 1,337 | 1,087 | 922.96 | 715.16 |
Working Capital | 11.56 | 11.7 | 4.4 | 41.32 | 47.69 |
Book Value Per Share | 0.01 | 0.01 | 0.01 | 0.06 | 0.10 |
Tangible Book Value | 1.83 | 3.01 | -1.63 | 28.96 | 46.38 |
Tangible Book Value Per Share | 0.00 | 0.00 | -0.00 | 0.03 | 0.06 |
Machinery | 2.11 | 2.29 | 2.93 | 2.81 | 2.66 |
Leasehold Improvements | 2.04 | 2.04 | 2.04 | 2.04 | 2.03 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.